跳至主要内容
临床试验/NCT00143377
NCT00143377已完成4 期

A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial To Evaluate The Effectiveness Of Detrusitol Sr 4mg On Patient's Perception Of Bladder Condition (PPBC).

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.0 个研究点目标入组 600 人开始时间: 2004年9月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
600
主要终点
Patient Perception of Bladder Condition at 12 weeks of treatment compared to placebo.

研究概览

简要总结

The purpose of this study is to evaluate the effectiveness of Detrusitol (tolterodine tartrate) SR, 4 mg once daily, on patient's perception of the symptoms of overactive bladder and which of these bothersome symptoms are improved with treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years or older patients suffering from OAB symptoms (urinary frequency of at least 8 micturitions per 24h, urinary urgency and at least 3 urge urinary incontinence episodes within 3 days), confirmed by a micturition bladder diary.

排除标准

  • Other than urge incontinence
  • History of prostate/uterine or other female organ cancer

结局指标

主要结局

Patient Perception of Bladder Condition at 12 weeks of treatment compared to placebo.

次要结局

  • Other safety and efficacy measures at 12 weeks of treatment.

研究者

发起方
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
申办方类型
Industry

相似试验